AstraZeneca PLC and U.S.-based Abraxis BioScience Inc. are considering ending their two-year marketing deal for breast cancer treatment Abraxane in the United States.
AstraZeneca said Tuesday that the Abraxis board will consider in early January whether to end the deal and reacquire exclusive marketing rights for the drug.
AstraZeneca paid $200 million for the rights to the …
No comments:
Post a Comment